Research programme: inhaled statin therapeutics - University of Calfornia/InVixa
Latest Information Update: 03 Feb 2021
At a glance
- Originator University of California, Davis
- Developer InVixa
- Class Anti-inflammatories; Antivirals
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical COVID-19 pneumonia; SARS-CoV-2 acute respiratory disease
Most Recent Events
- 19 Jan 2021 Research programme: inhaled statin therapeutics - University of Calfornia/InVixa is available for licensing as of 19 Jan 2021. https://www.invixainc.com/pipeline.html
- 19 Jan 2021 Preclinical trials in COVID-19 pneumonia in USA (Inhalation) before January 2021
- 19 Jan 2021 Preclinical trials in SARS-COV-2 acute respiratory disease in USA (Inhalation) before January 2021